TASFYGO tasurgratinib
Drug Class
FGFR inhibitorFGFR 酪氨酸激酶选择性抑制剂
Mechanism
Selectively binds to and inhibits FGFR2 kinase activity, preventing downstream phosphorylation and signaling cascades in FGFR2-fusion positive tumor cells.特异性结合并抑制 FGFR2 激酶活性，阻断 FGFR2 基因融合阳性肿瘤细胞内的下游磷酸化及信号传导通路。
Approved Indication
PMDA-approved in Japan for the treatment of unresectable biliary tract cancer (BTC) harboring FGFR2 gene fusions or rearrangements that has progressed after chemotherapy.日本PMDA批准用于治疗化疗后进展的、不可切除的、伴有 FGFR2 基因融合或重排的胆道癌 (BTC) 患者。
What This Means For Patients
TASFYGO is an FGFR2 selective inhibitor developed in Japan. It is approved by the PMDA for advanced biliary tract cancer with FGFR2 fusions, and is clinically accessible under Hainan pilot-zone regulations.TASFYGO 是一种在日本研发的高选择性 FGFR2 抑制剂。其已获日本 PMDA 批准用于治疗伴有 FGFR2 融合的晚期胆道癌，可在海南博鳌先行区内申请临床特许使用。
Regulatory Approvals
- PMDA — approved (2024) — source
Pivotal Clinical Evidence
No peer-reviewed pivotal trial on file yet.
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.